scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix Indication in Heart Failure

scPharmaceuticals announces FDA approval of sNDA expanding Furoscix indication in heart failure, now including NYHA Class IV patients.